Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 652

1.

Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.

Nordström T, Vickers A, Assel M, Lilja H, Grönberg H, Eklund M.

Eur Urol. 2015 Jul;68(1):139-46. doi: 10.1016/j.eururo.2014.08.010. Epub 2014 Aug 20.

2.

Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.

Carlsson S, Maschino A, Schröder F, Bangma C, Steyerberg EW, van der Kwast T, van Leenders G, Vickers A, Lilja H, Roobol MJ.

Eur Urol. 2013 Nov;64(5):693-9. doi: 10.1016/j.eururo.2013.04.040. Epub 2013 May 2.

3.

The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW, Roobol MJ.

Eur Urol. 2014 Dec;66(6):1109-15. doi: 10.1016/j.eururo.2014.08.011. Epub 2014 Aug 26.

4.

Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.

Bryant RJ, Sjoberg DD, Vickers AJ, Robinson MC, Kumar R, Marsden L, Davis M, Scardino PT, Donovan J, Neal DE, Lilja H, Hamdy FC.

J Natl Cancer Inst. 2015 Apr 11;107(7). pii: djv095. doi: 10.1093/jnci/djv095. Print 2015 Jul.

5.

A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.

Braun K, Sjoberg DD, Vickers AJ, Lilja H, Bjartell AS.

Eur Urol. 2016 Mar;69(3):505-11. doi: 10.1016/j.eururo.2015.04.028. Epub 2015 May 13.

6.

Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.

Grönberg H, Adolfsson J, Aly M, Nordström T, Wiklund P, Brandberg Y, Thompson J, Wiklund F, Lindberg J, Clements M, Egevad L, Eklund M.

Lancet Oncol. 2015 Dec;16(16):1667-76. doi: 10.1016/S1470-2045(15)00361-7. Epub 2015 Nov 10.

PMID:
26563502
7.

A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.

Parekh DJ, Punnen S, Sjoberg DD, Asroff SW, Bailen JL, Cochran JS, Concepcion R, David RD, Deck KB, Dumbadze I, Gambla M, Grable MS, Henderson RJ, Karsh L, Krisch EB, Langford TD, Lin DW, McGee SM, Munoz JJ, Pieczonka CM, Rieger-Christ K, Saltzstein DR, Scott JW, Shore ND, Sieber PR, Waldmann TM, Wolk FN, Zappala SM.

Eur Urol. 2015 Sep;68(3):464-70. doi: 10.1016/j.eururo.2014.10.021. Epub 2014 Oct 27.

PMID:
25454615
8.

Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.

Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, Lughezzani G, Scattoni V, Bini V, Freschi M, Sussman A, Ghaleh B, Le Corvoisier P, Alberola Bou J, Esquena Fernández S, Graefen M, Guazzoni G.

Eur Urol. 2013 Jun;63(6):986-94. doi: 10.1016/j.eururo.2013.01.011. Epub 2013 Jan 24.

PMID:
23375961
9.

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.

Vickers AJ, Cronin AM, Roobol MJ, Savage CJ, Peltola M, Pettersson K, Scardino PT, Schröder FH, Lilja H.

Clin Cancer Res. 2010 Jun 15;16(12):3232-9. doi: 10.1158/1078-0432.CCR-10-0122. Epub 2010 Apr 16.

10.

Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy.

Lughezzani G, Lazzeri M, Haese A, McNicholas T, de la Taille A, Buffi NM, Fossati N, Lista G, Larcher A, Abrate A, Mistretta A, Bini V, Palou Redorta J, Graefen M, Guazzoni G.

Eur Urol. 2014 Nov;66(5):906-12. doi: 10.1016/j.eururo.2013.12.005. Epub 2013 Dec 16.

PMID:
24361258
11.

Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.

Stattin P, Vickers AJ, Sjoberg DD, Johansson R, Granfors T, Johansson M, Pettersson K, Scardino PT, Hallmans G, Lilja H.

Eur Urol. 2015 Aug;68(2):207-13. doi: 10.1016/j.eururo.2015.01.009. Epub 2015 Feb 11.

12.

Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study.

Fossati N, Buffi NM, Haese A, Stephan C, Larcher A, McNicholas T, de la Taille A, Freschi M, Lughezzani G, Abrate A, Bini V, Palou Redorta J, Graefen M, Guazzoni G, Lazzeri M.

Eur Urol. 2015 Jul;68(1):132-8. doi: 10.1016/j.eururo.2014.07.034. Epub 2014 Aug 16.

PMID:
25139197
13.

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.

Vickers A, Cronin A, Roobol M, Savage C, Peltola M, Pettersson K, Scardino PT, Schröder F, Lilja H.

J Clin Oncol. 2010 May 20;28(15):2493-8. doi: 10.1200/JCO.2009.24.1968. Epub 2010 Apr 26.

14.
15.

Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.

Lazzeri M, Haese A, Abrate A, de la Taille A, Redorta JP, McNicholas T, Lughezzani G, Lista G, Larcher A, Bini V, Cestari A, Buffi N, Graefen M, Bosset O, Le Corvoisier P, Breda A, de la Torre P, Fowler L, Roux J, Guazzoni G.

BJU Int. 2013 Aug;112(3):313-21. doi: 10.1111/bju.12217.

16.

Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study.

Mearini L, Ferri C, Lazzeri M, Bini V, Nunzi E, Fiorini D, Costantini E, Manasse GC, Porena M.

Urol Int. 2014;93(2):135-45. doi: 10.1159/000356240. Epub 2014 Apr 8.

PMID:
24732975
17.

Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml(-1).

Chen R, Zhou LQ, Cai XB, Xie LP, Huang YR, He DL, Gao X, Xu CL, Ding Q, Wei Q, Yin CJ, Ren SC, Wang FB, Tian Y, Sun ZQ, Fu Q, Ma LL, Zheng JH, Ye ZQ, Ye DW, Xu DF, Hou JQ, Xu KX, Yuan JL, Gao X, Liu CX, Pan TJ, Sun YH; Chinese Prostate Cancer Consortium..

Asian J Androl. 2015 Nov-Dec;17(6):1017-21. doi: 10.4103/1008-682X.150846.

18.

Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.

Guazzoni G, Nava L, Lazzeri M, Scattoni V, Lughezzani G, Maccagnano C, Dorigatti F, Ceriotti F, Pontillo M, Bini V, Freschi M, Montorsi F, Rigatti P.

Eur Urol. 2011 Aug;60(2):214-22. doi: 10.1016/j.eururo.2011.03.052. Epub 2011 Apr 5.

PMID:
21482022
19.
20.

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.

Vickers AJ, Gupta A, Savage CJ, Pettersson K, Dahlin A, Bjartell A, Manjer J, Scardino PT, Ulmert D, Lilja H.

Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):255-61. doi: 10.1158/1055-9965.EPI-10-1003. Epub 2010 Dec 8.

Supplemental Content

Support Center